Downloads: 367

Files in This Item:
File Description SizeFormat 
s10549-011-1641-9.pdf461.43 kBAdobe PDFView/Open
Title: Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Authors: Kawaguchi, K  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-3161-7981 (unconfirmed)
Ishiguro, H  kyouindb  KAKEN_id
Morita, S  kyouindb  KAKEN_id
Nakamura, S
Ohno, S
Masuda, N
Iwata, H
Aogi, K
Kuroi, K
Toi, M  kyouindb  KAKEN_id
null
Author's alias: 石黒, 洋
Keywords: CYP3A4
Docetaxel
Drug exposure
Facial erythema
Hand-foot syndrome
H2 blocker
Issue Date: Nov-2011
Publisher: Springer Science+Business Media, LLC.
Journal title: Breast cancer research and treatment
Volume: 130
Issue: 2
Start page: 627
End page: 634
Abstract: Steroids and H2 blockers are commonly used as supportive care for taxane-containing chemotherapy, but they also affect docetaxel's primary metabolizer, cytochrome P450 3A4. This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently poorly understood. Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. We obtained data for 993 patients from 20 institutions. Twenty percent received H2 blockers, and all patients received dexamethasone. Univariate and multivariate analyses revealed that H2 blockers are associated with a significantly higher incidence of both HFS and FE. The incidence of FE was significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens combined. Dexamethasone usage did not affect the incidence of either HFS or FE. In conclusion, use of H2 blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk of both HFS and FE.
Rights: The final publication is available at www.springerlink.com
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/152167
DOI(Published Version): 10.1007/s10549-011-1641-9
PubMed ID: 21698408
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.